Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.10.2022 | Case report

Ipilimumab/nivolumab

Colitis: 3 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Anstadt EJ, et al. Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy. Oncologist 27: 799-808, No. 9, 2 Sep 2022. Available from: URL: http://doi.org/10.1093/oncolo/oyac108 Anstadt EJ, et al. Moderate Colitis Not Requiring Intravenous Steroids Is Associated with Improved Survival in Stage IV Melanoma after Anti-CTLA4 Monotherapy, But Not Combination Therapy. Oncologist 27: 799-808, No. 9, 2 Sep 2022. Available from: URL: http://​doi.​org/​10.​1093/​oncolo/​oyac108
Metadaten
Titel
Ipilimumab/nivolumab
Colitis: 3 case reports
Publikationsdatum
01.10.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-25478-5

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Nimesulide

Case report

Fentanyl